Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Active Placebo
16%
Active Treatment
16%
Acute Schizophrenia
33%
Acute Treatment
16%
Adverse Effects
16%
Amisulpride
16%
Antipsychotic Drugs
50%
Antipsychotics
100%
Baseline Scores
16%
Baseline Severity
33%
Baseline Symptoms
33%
Best Model
16%
Change Score
66%
Drug Group
16%
Ill Patients
50%
Initial Severity
100%
Inpatient Treatment
16%
Meta-analysis
100%
Mixed Model Repeated Measures
16%
Negative Symptoms
33%
Negative Symptoms of Schizophrenia
16%
Negative Syndrome
100%
Olanzapine
16%
Patient Benefit
16%
Patient Types
16%
Pivotal Trial
16%
Placebo
33%
Placebo Groups
16%
Placebo-controlled Study
100%
Randomized Clinical Trial
16%
Randomized Trial
16%
Remission
16%
Risperidone
16%
Scale Change
16%
Scale for the Assessment of Negative Symptoms
83%
Schizophrenia
100%
Schizophrenia Treatment
16%
Severely Ill Patients
33%
Symptom Change
16%
Symptom Improvement
16%
Symptom Score
66%
Symptom Severity
33%
Symptom Treatment
16%
Symptomatic Patients
16%
Medicine and Dentistry
Active Treatment
16%
Adverse Effect
16%
Amisulpride
16%
Antipsychotic Drug
50%
Clinician
33%
Meta-Analysis
100%
Negative Syndrome
50%
Olanzapine
16%
Placebo
66%
Placebo-Controlled Study
100%
Positive and Negative Syndrome Scale
100%
Randomized Clinical Trials
16%
Risperidone
16%
Scale for the Assessment of Negative Symptoms
83%
Schizophrenia
100%
Treatment of Schizophrenia
16%
Neuroscience
Adverse Effect
7%
Amisulpride
7%
Antipsychotic
21%
Meta-Analysis
100%
Negative Syndrome
100%
Olanzapine
7%
Placebo
100%
Positive Syndrome
42%
Risperidone
7%
Schizophrenia
100%
Treatment of Schizophrenia
7%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Effect
7%
Amisulpride
7%
Antipsychotic Drug
21%
Negative Syndrome
100%
Olanzapine
7%
Placebo
28%
Placebo-Controlled Study
100%
Positive Syndrome
42%
Randomized Clinical Trial
7%
Remission
7%
Risperidone
7%
Schizophrenia
100%